/Investor DB

Asabys Partners — 2023 Investments

4 investments dated 2023 · listed companies and verified rows first · show all

Nuagenuagetx.cominJun 2023✓ verified

Nuage Therapeutics develops drug discovery technologies for disordered proteins, focusing on precision treatments for aggressive cancers with limited therapeutic options.

AI & Machine LearningBiotechDeep TechBarcelona, ES

Mateusz Biesaga(Founder and Chief Technology Officer)inXavier Salvatella(Founder)in

Co-investorsSofinnova PartnersBStartup

Deepulldeepull.cominSeries B · Mar 2023 · $18M

Deepull develops a multiplex PCR diagnostic system to rapidly identify sepsis-causing pathogens and antibiotic resistance markers directly from blood samples in approximately one hour, targeting hospitals and clinical laboratories.

Medical Devices

Co-investorsKurma PartnersAlta Life SciencesColumbus Venture PartnersPanakes Partners

Orikine Bioorikine.bioinSeed · Jul 2023 · $6M

Orikine Bio develops engineered cytokines called Foldikines™ to reprogram immune responses for treating autoimmune and inflammatory diseases.

BiotechDeep TechHealthtechMedical DevicesBarcelona, ES

Ariadna Montero(Scientific Founder, Head of Innovation Management & Corp. Comm.)inAlejo Chorny(Co-founder & Former-CEO)inProf. Luis Serrano(Scientific Founder, Advisor)Dr. Javier Delgado(Scientific Founder, Advisor)Christian Pangratz(CEO & Board Director)in

BoardLarry Edwards(Chairman of the Board)

Co-investorsAdBio partners

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Gradient Denervation Technologies

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.